FDA Rules Against Avastin
Today, December 16, the US Food and Drug Administration (FDA) took steps to disallow the use of Avastin (bevacizumab) in breast cancer. This overturns the previous director’s approval of the drug two years ago–a decision that was medically unwarranted but was worth hundreds of millions of dollars to Roche.
Dr. Richard Pazdur, the FDA’s chief of cancer drug review, said, “Given the number of serious and life-threatening side effects, the FDA does not believe there is a favorable risk-to-benefit ratio.”
I applaud this decision, as the data behind the use of Avastin in breast cancer was always very shaky. The company, however, is expected to appeal the ruling.